Muutke küpsiste eelistusi

Metabolic Syndrome: The Road Map from Inflammation to Cardiovascular Disease, ICS 1303: Proceedings of the 9th European Symposium on Metabolism, held in Padua, Italy, between 12 and 14 October 2006, Volume 1303 [Kõva köide]

Edited by (Department of Clinical and Experimen), Edited by (Deparment of Clinical and Experimental Medicine, Metabolic Diseases, Policlinico, Padova, Italy), Edited by (Istituto di Neuroscienze, Consiglio Nazionale delle Ricerche - Seizone de Padova, Padova, Italy)
  • Formaat: Hardback, 188 pages, kõrgus x laius: 240x165 mm, kaal: 490 g
  • Sari: International Congress
  • Ilmumisaeg: 29-Aug-2007
  • Kirjastus: Elsevier
  • ISBN-10: 044452889X
  • ISBN-13: 9780444528896
Teised raamatud teemal:
  • Kõva köide
  • Hind: 149,05 €*
  • * saadame teile pakkumise kasutatud raamatule, mille hind võib erineda kodulehel olevast hinnast
  • See raamat on trükist otsas, kuid me saadame teile pakkumise kasutatud raamatule.
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Lisa soovinimekirja
  • Formaat: Hardback, 188 pages, kõrgus x laius: 240x165 mm, kaal: 490 g
  • Sari: International Congress
  • Ilmumisaeg: 29-Aug-2007
  • Kirjastus: Elsevier
  • ISBN-10: 044452889X
  • ISBN-13: 9780444528896
Teised raamatud teemal:
This collection of papers represents an edited version of the Proceedings of the 9th European Symposium on Metabolism which was held at the University of Padua (Italy) from October 12-14, 2006. As did the Symposium itself, this work unites under a single cover topics dealing with four important metabolic alterations: diabetes, obesity, hyperlipidemia and hypertension. Of vital interest to the scientific community because of their cost in human life and medical expenditure, the latest edition of this Symposium received much attention from investigators in these fields. The 2006 edition focusses on the most recent epidemiologic findings on the role of oxidative stress and of endothelial dysfunction on the development of atherosclerosis. Other topics of particular interest are: abdominal obesity, pro-inflammatory adipokines and atherogenesis; the metabolic syndrome and cardiovascular global risk; coronary and cerebrovascuclar disease in diabetes and in the metabolic syndrome. Finally, the management, prevention and treatment of the metabolic syndrome and its cardiovascular complications are examined in the light of several recent clinical trials in these fields. This volume will certainly be of interest to all those practitioners and specialists who are looking for a broad, though specific overview on several aspects of insulin resistance as a possible pathogenetic mechanism and a guide to preventing and treating the metabolic syndrome and its cardiovascular complications in their patients.
Acknowledgements and Introduction v
Preface vii
Is the metabolic syndrome still alive?
1(20)
The metabolic syndrome: Is it still alive?
3(7)
E. Bonora
Global management of high risk patients: Integrated primary cardiovascular prevention in diabetics
10(11)
A.A. Conti
M. Minelli
G.F. Gensini
The metabolic syndrome: a widespread inflammatory disease
21(28)
Inflammation and macrophage infiltration in adipose tissue: A link between diabetes and atherosclerosis
23(8)
R. Menghini
R. Lauro
M. Federici
Adipokines, systemic inflammation and inflamed adipose tissue in obesity and insulin resistance
31(4)
U. Smith
C.X. Andersson
B. Gustafson
A. Hammarstedt
P. Isakson
E. Wallerstedt
Oxidative stress, inflammation and atherosclerotic plaque development
35(6)
F. Cipollone
M.L. Fazia
A. Mezzetti
Insulin signaling in hypertension
41(8)
B. Trimarco
S. Crispo
C. Morisco
The metabolic syndrome: the significance of microvascular and macrovascular diseases
49(34)
Diabetic nephropathy: An update on renal structure
51(9)
P. Fioretto
M. Bruseghin
I. Barzon
M. Arboit
M. Dalla Vestra
Erectile dysfunction as a predictor of cardiovascular risk
60(5)
P. Montorsi
Cerebrovascular disease in type 2 diabetes
65(5)
M. Laakso
J. Kuusisto
Coronary heart disease in diabetes
70(4)
A. Avogaro
G. Fadini
S. Vigili de Kreutzenberg
A. Tiengo
Atherothrombotic disease and the metabolic syndrome
74(9)
G. Davi
F. Santilli
Dyslipidemia in the metabolic syndrome: genes and environment
83(28)
Premature coronary artery disease and apolipoprotein B and apolipoprotein A-I
85(10)
A.F. Ayyobi
A. Zambon
J.D. Brunzell
The role of genetic predisposition and biomarkers in atherosclerosis
95(8)
G. Assmann
H. Schulte
U. Seedorf
The anti-atherogenic properties of HDL particles
103(8)
G. Zuliani
G.B. Vigna
R. Fellin
The metabolic syndrome: the treatment of complex disease(s)
111(62)
Global cardiovascular risk: The benefits of a precocious, aggressive treatment strategy
113(8)
C. Bilato
S. Iliceto
Inhibition of synthesis and absorption of cholesterol: A new option in managing hypercholesterolemia
121(8)
L. Grigore
G.D. Norata
A.L. Catapano
Life (Iosartan intervention for endpoint reduction in hypertension) study and its substudies
129(9)
C. Borghi
S. Ertek
When and how to restore β-cell function?
138(8)
F. Pancani
R. Lupi
R. Miccoli
P. Marchetti
S. Del Prato
The blockade of the endocannabinoid CB1 receptors and its influence on cardiometabolic risk: Lesson from Rimonabant In Obesity (RIO) trials
146(9)
R. Vettor
M. Rossato
F. Fallo
C. Pagano
Efficacy and safety of pioglitazone: The proactive study
155(5)
P. Brunetti
Lifestyle and outcome among patients with type 2 diabetes
160(13)
G. Hu
J. Tuomilehto
Author index 173(2)
Keyword index 175